Stockreport

Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF CARMIEL, Israel, Nov. 27, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, p [Read more]